NasdaqGS:BIIBBiotechs
Assessing Biogen (BIIB) Valuation After Breakthrough Therapy Status And Positive Lupus Trial Data
Biogen (BIIB) is back in the spotlight after the FDA granted Breakthrough Therapy Designation to its spinal muscular atrophy candidate salanersen, alongside encouraging Phase 3 lupus data for dapirolizumab pegol presented with partner UCB.
See our latest analysis for Biogen.
The recent FDA Breakthrough Therapy Designation for salanersen and positive lupus data arrive as Biogen’s share price trades at US$195.34, with a 1-year total shareholder return of 45.61% contrasting with weaker 3 and 5...